Welcome to the clinical data market
A primer on the players, revenue models, and issues in today's clinical data market—including a brief discussion of the potential effect of synthetic data on the clinical data market.
At a glance
Read on to get our full commentary, or use the links below to jump to a specific area of interest:
-
Background: What is the clinical data market? Where did it…
-
Why has it been ‘easier said than done’ to monetize…
-
How provider partnerships with third-party aggregators have expanded the clinical…
-
Players in the clinical data market
-
Contract mechanics in clinical data market world
-
Pricing
-
OK so — what about synthetic data? What is it,…
-
I see where this is going. So synthetic data could…
A primer to establish what’s what before tackling the next-level question: What will the advent of synthetic data do to the clinical data market?
Having researched corporate innovation at health systems, I know system leaders have long been interested in figuring out ways to monetize clinical data. It makes sense: if systems could manage to sell or license de-identified data in their EHRs to life science or tech companies, that would be very helpful from a revenue diversification perspective. Especially whenever core inpatient economics are under siege.
But, it’s always been an easier-said-than-done proposition. And NOW, maybe there’s also a new spoiler in the mix, in the form of ‘synthetic data’. Synthetic data = AI-created, de-identified, no-patient-privacy-risk datasets that have the same statistical characteristics as actual clinical datasets.
Union Healthcare Insight
Log in to continue reading
Not a member yet? Create a free account for limited access.
Related insights
Healthcare’s next forced efficiency leap is AI. Where does your organization stand?
The health-system utilization forecasting conundrum: One size definitely doesn’t fit all.
Key takeaways from our Chicago Revenue Cycle Summit